centre of the retina (a process known as choroidal neovascularisation). These vessels easily haemorrhage and cause lesions on the macula, leading to visual impairment. Dry AMD (non-neovascular) is a form of extensive atrophy (wasting) of cells which progresses slowly, whilst the wet form leads to a rapid worsening of vision.
There are about 26,000 new cases of wet AMD in the UK each year and the condition affects more women than men. By definition the condition usually affects people who are over 50 years old and the risk increases significantly with age. The most cited risk factor for AMD is cigarette smoking, with research showing that former smokers have a 3.6 times greater risk of AMD compared to people who have never smoked.
Choroidal neovascularisation (CNV) is classified according to its appearance on fluorescein angiography (a technique used to examine blood vessels in the retina). The classifications are:
• classic with no occult (classic CNV lesions with no evidence of an occult component)
• predominantly classic with occult (classic CNV forms at least 50% of the lesion but some occult CNV is present)
• minimally classic (classic CNV makes up less than 50% but more than 0% of the lesion)
• occult only (no classic CNV seen). 
The technologies
Ranibizumab and pegaptanib both inhibit the activity of vascular endothelial growth factor (VEGF) and are commonly known as anti-VEGFs. Ranibizumab is a humanized therapeutic antibody fragment that binds to VEGF-A isoforms.
Pegaptanib is a pegylated modified oligonucleotide that binds to VEGF-165.
Both drugs reduce new vessel growth and leakage.
Both drugs hold UK marketing authorisations for the treatment of neovascular (wet) age-related macular degeneration and are administered by intravitreal injection into the affected eye. Pegaptanib should be administered once every six weeks (nine injections per year). Ranibizumab treatment is initiated with a loading phase of one injection per month for three consecutive months, followed by a maintenance phase in which patients should be monitored for visual acuity on a monthly basis. If the patient experiences a loss of more than 5 letters in visual acuity (ETDRS or one Snellen line equivalent), ranibizumab should not be shorter than one month.
Anti-VEGFs are associated with adverse events which may be related to the intravitreal injection or to the drugs themselves. The adverse events may be eye-related (ocular) or systemic, and can include vitreous floaters, conjunctival haemorrhage, eye pain, increased intraocular pressure, intraocular inflammation, ocular or periocular infections, endophthalmitis (severe infection inside the eye), hypersensitivity reactions, and retinal detachment. 
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Pegaptanib
The combined results of two concurrent RCTs comparing doses of 0.3, 1.0 and 3.0 mg pegaptanib with sham injection (one carried out in the USA and Canada, the other at centres worldwide) were published as the VISION study.
A total of 1208 patients, with all types of CNV lesion were included. Patients were followed for up to 54 weeks, then for a further 48 weeks after rerandomisation.
Ranibizumab
Four RCTs of ranibizumab (MARINA, ANCHOR, PIER, FOCUS) were included in the Assessment Report and manufacturer's submission. For details of the interventions, comparators and CNV lesion types in the four RCTs, please refer to table 5 of this overview. The length of follow-up in the trials varied from 12 to 24 months and the doses used were 0.3 mg and 0.5 mg. Outcomes were assessed at different time points and trials had a different number and frequency of injections given to the intervention group.
Assessment of effectiveness outcomes
The main outcomes measured in the RCTs were:
Ranibizumab and pegaptanib for age-related macular degeneration Patients treated with both pegaptanib and ranibizumab gained in visual acuity.
The proportion gaining 15 or more letters was higher for ranibizumab than for pegaptanib.
In the VISION study (pegaptanib), statistically significantly more patients in the 0.3 mg group gained at least five letters (22%) compared with 12% for the sham group (p = 0.004). Gains of at least 10 letters were also reported for 11% of the 0.3 mg pegaptanib group (p=0.02) compared to 6% of the sham injection group. Very few patients gained more than 15 letters.
A third of the 0.5 mg ranibizumab group gained at least 15 letters compared to 4% of the sham group at 24 months in the MARINA RCT. In the ANCHOR trial, 40% of the 0.5mg ranibizumab group gained at least 15 letters compared to 6% of the PDT sham injection group. In the FOCUS study, 24% of the 0.5mg ranibizumab + PDT group compared to 5% of the sham injection + PDT group gained at least 15 letters (p=0.0033).
Mean change in visual acuity
Pegaptanib
Mean loss of letters at week 54 was higher in the sham group than in the 0.3 mg group. Losses of 7.5 letters were observed in the 0.3 mg pegaptanib group, compared with a mean loss of 14.5 letters in the sham injection group.
Ranibizumab
The MARINA, ANCHOR and FOCUS trials all reported mean increases in visual acuity in the 0.5 mg ranibizumab group compared to the sham injection group. Gains in letters ranged from 4.9 in the FOCUS trial (0.5 mg ranibizumab plus PDT group) to 11.3 letters in the ANCHOR study (0.5 mg ranibizumab group). Corresponding losses in the sham groups were 8.2 letters in the FOCUS trial and 10.5 letters in the MARINA trial and these differences were statistically significant. PIER trial patients experienced a decrease in visual acuity and this may have been because doses were administered every three months instead of monthly as in the other trials. For
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Deterioration to legal blindness
Legal blindness was defined in the studies as the Snellen equivalent of 20/200 (6/60) or worse.
Pegaptanib
By the end of the first year VISION study 56% of patients in the sham group were legally blind in the study eye compared to 38% in the 0.3 mg pegaptanib group. After re-randomisation at week 54, only one extra patient who continued the 0.3 mg dose had deteriorated to legal blindness compared to 14% who discontinued the 0.3 mg dose after one year. In the second year of the VISION study, approximately 34% of those randomised to continue with 0.3mg pegaptanib were legally blind compared with 24% of those randomised to discontinue 0.3mg pegaptanib and 47% of those in the control arm.
Ranibizumab
In the PIER study, *** of patients in the ranibizumab group deteriorated to legal blindness compared to over *** in the sham group. A total of 15% of patients in the MARINA trial reached the level of legal blindness in the 0.5mg ranibizumab group compared with 48% in the sham group at 24 months. In the ANCHOR trial, 60% of patients receiving sham injection deteriorated to legal blindness compared with 16% receiving 0.5 mg ranibizumab and PDT at 24 months. Please refer to table 3.5 on page 65 of the Assessment Report for more details.
Anatomical changes from baseline
Pegaptanib
The VISION study reported a slower rate of increase in CNV lesions between baseline and week 54 for the 0.3 mg compared with the sham group (1.8 disc areas for 0.3mg group vs 2.5 disc areas for the sham group). Of those who continued with pegaptanib after 54 weeks, mean lesion size was 5.4 disc injections is a critical factor in the effectiveness of ranibizumab.
Change in visual function questionnaire scores (NEI VFQ-25)
This outcome was reported for ranibizumab only. In the MARINA (ranibizumab) trial there was an ******** of nearly * points in the mean near activities score for ranibizumab patients compared with a mean ******** of *** points in the sham group. Both ranibizumab groups showed an ******** of about * points in distant activities score compared with a mean ******** of *** points for the sham group. The ANCHOR trial found ************** in near activities score. All treatment groups showed an *********** in the distant activities score but mean scores were ******************** for the ranibizumab treatment group than for the PDT group. The PIER study showed ************* between treatment and sham groups which may have been a result of the reduced dose frequency in this study.
Disease modifying effect
This outcome was reported for pegaptanib only. A study reported that the risk of non-response at the end of two years was lower for people who discontinued pegaptanib after a year compared to those who had never
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Overview received the drug. The Assessment Group considered this to be evidence of a disease modifying effect, which is biologically plausible because anti-VEGF drugs target the underlying disease rather than just treat the symptoms of AMD. However, it also noted that the decline in the proportion of responders (those losing less than 15 letters) from 54 weeks to 102 weeks in the VISION study was the same for those who received the 0.3 mg dose and those who had never received the drug (14%).
Adverse Events
Pegaptanib
In the VISION study most adverse events reported were mild to moderate events. They were similar between treatment arms except for vitreous floaters, vitreous opacities, and anterior chamber inflammation after one year of treatment. Eye related adverse events were more common in the study eye among patients in the sham injection group suggesting that the preparation procedure itself (which included an ocular antisepsis procedure and an injection of subconjunctival anaesthetic) may be associated with adverse effects. Endophthalmitis affected about 1.3% of the patients in the first year.
Of these, two thirds had been affected by protocol violation (for example, failure to use aseptic technique).
Ranibizumab
In the ranibizumab studies, most adverse events were also mild to moderate.
Conjunctival haemorrhage was the most widely reported eye related adverse effect, but incidence varied between the ranibizumab RCTs and it was also high in the control groups. More ranibizumab patients than control patients experienced increased intraocular pressure and vitreous floaters.
Endophthalmitis affected approximately 1% and 0.7% of patients in the MARINA and ANCHOR RCTs respectively. In the FOCUS trial, intraocular inflammation was ************ in the ranibizumab + PDT group compared to **** in the PDT + sham group.
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Subgroup analysis
Main outcomes examined were mean decrease in visual acuity by lesion type and CNV status. Consultees indicated that consideration of subgroups by CNV lesion type and baseline visual acuity may be important to consider.
More details on subgroup analysis can be found on page 66-68 of the Assessment Report.
Cost effectiveness
Published literature
The Assessment Group identified a total of 421 publications relating to costeffectiveness in AMD. None of these were a fully published economic 
Manufacturer submissions
Both manufacturers provided economic evaluations. The manufacturers' models took an NHS and personal social services perspective. In addition both models used evidence-based data for the first two years after which there was extrapolation based on the life expectancy of the cohort. Both models used a Markov approach with the states being different levels of visual acuity and death. Costs and benefits in both cases were discounted at 3.5%.
There was no direct or indirect comparison of the two technologies.
The Pfizer model -pegaptanib
The The model has 12 states, defined by declining visual acuity from 6/12 through to 6/96 and an additional absorbing state -death. However, a visual acuity of 6/12 is regarded clinically as the point at which the disease is likely to lead to major impairment of quality of life, for example, the point where a person cannot drive. The base-case analysis is based on all lesion types. Treatment was stopped if visual acuity dropped below 6/96 or by six or more lines from baseline at the end of a year. This is referred to as scenario A and the costeffectiveness of treatment adopting an alternative stopping rule, labelled scenario B, with a higher threshold visual acuity (6/60) for discontinuing pegaptanib treatment, is also reported in the submission.
Cycle length in the model is six weeks, and there is a ten year horizon (life expectancy of patients with a mean age of 77). The Assessment Group indicated that no adjustments were made to quality of life scores for patients experiencing adverse events and no adverse events were reported for the usual care cohort even though they were expected for PDT. The analysis was based on the treatment of the patients' better-seeing eye only and the Assessment Group commented that the incremental cost-effectiveness ratios (ICERs) for the treatment of the worst eye or both may be higher. See table 3 below for the base case results of these two scenarios.
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Overview Results for sensitivity analysis carried out by the manufacturer showed that the costs and probabilities of receiving visual impairment services and the model time horizon had a significant effect on the ICERs. For example, the ICER for a three year time horizon was between £55,000 and £60,000 per QALY, reducing to £30,000 per QALY when the time horizon was increased to five years. The Assessment Group argues that this reflects the fact that treatment costs are incurred in the first two years with benefits being projected over the patient's lifetime. Similarly when costs and probabilities of receiving services for visual impairment are set at the upper limits, then pegaptanib treatment dominates usual care, whereas if they are set to the lower limit the ICER is around £25,300 per QALY for scenario A and about £24,200 per QALY for scenario B. When age was considered in the sensitivity analysis, the ICER was reduced to about £10,900 for base-case (about £9,500 for scenario B) for patients under 75 years and about £18,900 for base-case (£17,100 for scenario B) for patients above 75 years.
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Sensitivity analysis by the Assessment Group using the Pfizer model
The Assessment Group tested the sensitivity of cost effectiveness estimates to changes in assumptions on resource use for patient monitoring. The cumulative effect of the changes is to increase the ICER from about £15,800
per QALY gained in the base-case to about £22,300 per QALY gained. When the injection procedure is costed as a day case procedure, the ICER increases to about £35,200. Please refer to table 4. 
Novartis model
The Assessment Group noted that the Novartis submission compared the use of ranibizumab with best supportive care for patients with minimally classic or occult no classic lesions, and with both PDT with verteporfin and best supportive care for patients with predominantly classic lesions. The different types of wet AMD were analysed separately based on results from four RCTs (ANCHOR for predominantly classic, MARINA for minimally classic and occult no classic, PIER for all lesion types). Please refer to table 5 for more details on the trials. Because the ANCHOR trial did not include a sham arm, the Assessment Group noted that comparison of treatment with ranibizumab against best supportive care for predominantly classic patients was made through indirect comparison using data from the TAP study in which PDT was compared with best supportive care. MARINA trial data was also used to estimate the natural history of the disease for extrapolating trial outcomes over ten years. Assessment Group noted that the results reported here are based on the assumption that frequency of dosage of ranibizumab can be reduced, from twelve to eight injections (the latter including a loading dose of monthly injections for the first three months) in year 1 and from twelve to six injections in year 2, without reducing its effectiveness.
Sensitivity analysis by the Assessment Group using the Novartis model
The Assessment Group carried out sensitivity analysis on some of the key parameters in the manufacturer's model, listed in table 6 
Assessment group model
The Assessment Group's model was based on the cost effectiveness of ranibizumab and pegaptanib compared with current practice (PDT with verteporfin for classic no occult lesions or predominantly classic lesions if the evidence-base is limited and best supportive care). They used the following clinically accepted categories of response; intermediate vision loss (loss of 15 to 30 letters) and severe vision loss (loss of more than 30 letters). The estimated impact of these changes on visual acuity was measured using a Markov state transition model.
A six state Markov model was developed and the rate of disease progression was expressed as the reduced probability of progressing to a lower level of visual acuity health state in each model cycle. The model extrapolated the effects of the two year trial period to 10 years in both arms of the model.
Given that pegaptanib and ranibizumab treatments are assumed to have stopped by year 2, benefits were assumed to decline at the same rate as those for usual care, although from a higher level of visual acuity.
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The Assessment Group also assumed that patients only benefit while on treatment with both drugs and that all patients experience a rapid worsening of their condition as soon as treatment stops, reverting to the state of visual deterioration they would have reached had they received no treatment. The costs of adverse events of the treatments were also included in the model.
Health state utilities reported by Brown et al were used as they are considered to be the most credible published utility values for visual loss associated with AMD.
Cost effectiveness of pegaptanib in Assessment Group model
The Assessment Group estimated the base case ICER for pegaptanib compared with usual care to be £ 31,000 per QALY over a 10 year time horizon.
Sensitivity analysis in the Assessment Group model for pegaptanib
The Assessment Group carried out a sensitivity analysis of different assumptions used in their model. Time horizon has a strong effect on costeffectiveness estimates. As the time horizon increases the incremental cost of pegaptanib reduces and the incremental QALY gain increases. In addition, the excess costs of treatment are all incurred in the first two years. The Assessment Group reported that the more rapid disease progression in the usual care cohort leads to increased costs associated with services for visual impairment, which offset an increasing proportion of treatment costs for the pegaptanib cohort.
The Assessment Group also performed a sensitivity analysis to reflect the disease modifying effect of pegaptanib. Based on an analysis of non-response (that is, loss of at least 15 letters of visual acuity from baseline) in patients randomised to discontinue treatment after one year and those who were never treated, it has been suggested that pegaptanib treatment is associated with a 30% reduction in non-response. This relative risk reduction was applied to the estimated transition probabilities for losing three to six lines and losing greater Ranibizumab and pegaptanib for age-related macular degeneration Page 18 of 26
Overview than six lines of visual acuity in the sensitivity analysis. Since this effect has only been demonstrated for patients in the year following discontinuation of treatment, it was first applied only in year three of the ten year model.
Varying the distribution of initial visual acuity has a significant effect on the ICER. A cohort equally split between the 6/12 and 6/24 and 6/24 and 6/60
states produced an ICER of approximately £35,900, while a cohort with initial visual acuity of 6/24-6/60 produced an ICER of approximately £46,300.
When a higher cost is assumed for providing injections as a day procedure, the ICER increases substantially to £47,800. The costs of blindness, in particular the costs of uptake of services (estimated as the proportion of eligible cases with visual acuity of less than 6/60 receiving services), had an effect on the cost effectiveness.
In terms of probabilistic sensitivity analysis, pegaptanib had a probability of being cost effective (compared to usual care) of 17% at a WTP threshold of £20,000 per QALY and 58% at a WTP threshold of £30,000 per QALY. Table 7 reports the assumptions described above which had a substantial impact on the ICERs. The costs of blindness are between 24% and 54% of total costs for ranibizumab patients. While the difference between cost of blindness in the ranibizumab and comparator cohorts at ten years does not fully offset the costs of treatment with ranibizumab, the increased proportion of total costs accounted for by progression to greater visual impairment and blindness, together with the increased QALY gain, yields the lower ICERs reported in table 8 above.
Sensitivity analysis in the Assessment Group model for ranibizumab
The results of the sensitivity analysis reported here are those with a strong effect on cost effectiveness estimates. The full sensitivity analysis can be found in the Assessment Report on pages 145-147.
As the time horizon is reduced from the extrapolated 10 years the ICERs increase (see table 9 The results also showed that the cost effectiveness estimates were most sensitive to assumptions over uptake, estimated as the proportion of eligible cases (that is, with visual acuity less than 6/60) receiving services. Using high uptake and high unit cost estimates produces a situation where ranibizumab is dominant (lower cost with better outcome) compared with either PDT or best supportive care for patients with predominantly classic lesions. However when low costs and medium uptake assumptions are used, the ICERs generally increase from baseline. Please refer to table 9.
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Summary base-case results for both drugs (Assessment Group model, 10 year time horizon)
Tables 10 and 11 below summarise the base-case results for both drugs and the probability of the drugs being cost effective at a WTP threshold of £20,000 and £30,000 per QALY. 
Issues for consideration
• Ranibizumab is used in a different dose frequency regimen (lower frequency of injections) in the pivotal RCTs to that recommended in the marketing authorisation. How does this impact on considerations of its clinical and cost effectiveness?
• Current NICE guidance recommends PDT for patients with classic with no occult lesions, and not in those with predominantly classic lesions except in clinical trials. What is current practice in England and Wales and how does this impact on the cost-effectiveness evidence for anti-VEGF drugs compared with PDT?
• The analyses are based on treating the eye with better vision only. How might this affect considerations of the cost effectiveness of pegaptanib?
• There are no head-to-head trials comparing ranibizumab with pegaptanib. No indirect comparisons have been performed due to differences in RCT populations.
• Possible subgroups might be defined by CNV lesion type or by baseline visual acuity. Is there any evidence to suggest that clinical or cost effectiveness for any such group differs from others?
• Consultees state that recurrent CNV on cessation of treatment is highly likely. What are the considerations of how disease progression after ceasing treatment has been modelled?
• Costs: Do the costs of monitoring, administration, and rehabilitation in the models reflect clinical practice and are the assumptions for projecting them over 10 years reasonable? For example, how often are 
Ongoing research
There are currently a number of phase II and III trials of anti-VEGF treatments for AMD which are ongoing or about to start. These include:
• Protocol EOP1009 -A phase II trial to assess the effect of pegaptanib sodium on foveal thickening in patients with exudative subfoveal AMD.
• A phase IIIb/IV trial to compare the safety and efficacy of intravitreal injections of pegaptanib. Expected completion: October 2008.
NCT00134667.
• An exploratory randomized trial to explore the safety and efficacy of three different doses of intravitreous injections of pegaptanib in patients with subfoveal neovascular (AMD). Expected completion: June 2009.
NCT00312351.
• HORIZON: a phase III trial in patients with subfoveal CNV secondary to AMD. Sham injection control. Objectives: to investigate long-term safety, tolerability and efficacy of multiple intravitreal ranibizumab.
Completion date not given.
• SAILOR: phase IIIb single-masked, 1 year multicentre study (NCT00299078). The primary outcome is the incidence of serious adverse events in ranibizumab treated patients. Study start: March 2006. Completion date not given.
• Verteporfin photodynamic therapy cohort study for the UK. This is a study aimed at describing the provision and outcomes of PDT in NHS setting. Relationship between QoL/resource use and VA can be extrapolated to existing RCT findings from this study. Expected completion date: 31 December 2007
